Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The reader is cautioned not to place undue reliance on any forward-looking information. Important factors that could cause actual results to differ materially from the Company's expectations including the risks detailed from time to time in the Company's public disclosure. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. This news release contains forward-looking statements. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.

Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of integrative mental health clinics and operates a full-service contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics and clinical research sites. Net loss and comprehensive loss for the period Realized gain on disposition of marketable securities Realized gain on settlement of convertible debenture Unrealized (loss) gain of marketable securities and convertible debentures Unveiled new Company logo and announced rebrand of all subsidiary clinics and research sites Secured insurance coverage for direct billing of intravenous ketamine for treatment-resistant depression from four major health insurance providers: Blue Cross Blue Shield, the University of Utah, PEHP Health & Benefits and MBA Benefit Administrators Opened a new clinic and third research site in Murray, Utah, featuring a new specialized care and research program, Psychedelic Palliative Care by Novamind Leased new clinic to meet patient demand in Utah, the Wheeler Park Clinic, scheduled to open in early 2022 Signed letter of intent ('LOI') to acquire Arizona-based mental health practice, Foundations for Change, the first announcement from a pipeline of accretive transactions Our clinical research business has been actively building an exciting pipeline of contracts with leading drug developers.'ДЇiscal Q1 2022 Operating Results and Subsequent Events 'We continue to make progress on our national clinic expansion, most recently with a letter of intent to acquire two locations in Arizona.

'Q1 was a strong start to fiscal year 2022, driven by the addition of another clinic to our network and increased patient demand for our comprehensive range of innovative mental health treatments,' said Yaron Conforti, Novamind's CEO and Director. All results are reported under International Financial Reporting Standards and in Canadian dollars, unless otherwise specified. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ('Novamind' or the 'Company'), a leading mental health company specialized in psychedelic medicine, reported its fiscal first quarter results for the three months ended Septem('Fiscal Q1 2022'). TORONTO, ON / ACCESSWIRE / Novem/ Novamind Inc.

Total working capital of $6,834,011 to fund operations Total revenue of $1,857,750, +113% when compared to same period last year Multistate expansion underway, signed LOI to acquire Arizona-based mental health practice

Novamind logo